VEGFA and ovarian carcinoma: Dual blockade of the VEGF and EGFR pathways bevacizumab in combination with erlotinib in recurrent ovarian cancer was not superior to bevacizumab alone and the incidence of grade-3 diarrhoea was higher than expected.